Global Information
회사소개 | 문의 | 비교리스트

특이단백질 : 의료기기 파이프라인 평가

Specific Proteins - Medical Devices Pipeline Assessment, 2019

리서치사 GlobalData
발행일 2019년 12월 상품 코드 666938
페이지 정보 영문 123 Pages
가격
US $ 4,000 ₩ 4,816,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,000 ₩ 9,632,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 12,000 ₩ 14,448,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


특이단백질 : 의료기기 파이프라인 평가 Specific Proteins - Medical Devices Pipeline Assessment, 2019
발행일 : 2019년 12월 페이지 정보 : 영문 123 Pages

특이단백질(Specific Proteins)의 파이프라인 제품에 대해 조사 분석했으며, 개발 단계별 비교 분석에 초점을 맞추어 주요 기업, 진행중인 임상시험 등의 정보를 전해드립니다.

제1장 목차

제2장 서론

  • 특이단백질 개요

제3장 개발중인 제품

  • 특이단백질 - 파이프라인 제품 : 개발 단계별
  • 특이단백질 - 파이프라인 제품 : 지역별
  • 특이단백질 - 파이프라인 제품 : 규제 경로별
  • 특이단백질 - 파이프라인 제품 : 승인 예정일별

제4장 특이단백질 - 개발중인 파이프라인 제품 : 기업별

  • 특이단백질 기업 - 파이프라인 제품 : 개발 단계별
  • 특이단백질 - 파이프라인 제품 : 개발 단계별

제5장 특이단백질 기업과 제품 개요

  • Alfa Wassermann Diagnostic Technologies, LLC
  • Amerimmune
  • Analyticon Biotechnologies AG
  • Beckman Coulter Inc
  • China Medical Technologies Inc(Inactive)
  • Colorado State University
  • ELITechGroup Inc
  • Fujirebio Diagnostics Inc
  • Genesis Detection Systems, Inc.
  • Genome Diagnostics Pvt. Ltd.
  • Guanine Inc
  • InDevR Inc
  • Kobe University
  • Ottawa Hospital Research Institute
  • Sebia SA
  • Siemens Healthcare GmbH
  • The Binding Site Group Ltd
  • The Chinese University of Hong Kong
  • University of California

제6장 특이단백질 - 최근의 동향

제7장 부록

KSM 18.08.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 1: Specific Proteins - Pipeline Products by Stage of Development 11
  • Table 2: Specific Proteins - Pipeline Products by Territory 12
  • Table 3: Specific Proteins - Pipeline Products by Regulatory Path 13
  • Table 4: Specific Proteins - Pipeline Products by Estimated Approval Date 14
  • Table 5: Specific Proteins Companies - Pipeline Products by Stage of Development 15
  • Table 6: Specific Proteins - Pipeline Products by Stage of Development 17
  • Table 7: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 20
  • Table 8: Alinity c Assay - Cystatin C - Product Status 20
  • Table 9: Alinity c Assay - Cystatin C - Product Description 20
  • Table 10: Alinity c Assay - Immunoglobulin E - Product Status 21
  • Table 11: Alinity c Assay - Immunoglobulin E - Product Description 21
  • Table 12: Alfa Wassermann Diagnostic Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 13: ACE Axcel System - Lp(a) Assay - Product Status 22
  • Table 14: ACE Axcel System - Lp(a) Assay - Product Description 22
  • Table 15: ACE Axcel System - Microalbumin Assay - Product Status 23
  • Table 16: ACE Axcel System - Microalbumin Assay - Product Description 23
  • Table 17: ACE Axcel System - Transferrin Assay - Product Status 23
  • Table 18: ACE Axcel System - Transferrin Assay - Product Description 23
  • Table 19: Amerimmune LLC Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 20: FoxP3 Protein Expression Assay - Product Status 25
  • Table 21: FoxP3 Protein Expression Assay - Product Description 25
  • Table 22: Wiscott-Aldrich Protein Expression Assay - Product Status 26
  • Table 23: Wiscott-Aldrich Protein Expression Assay - Product Description 26
  • Table 24: Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 25: Turbitex C 3c Reagent - Product Status 27
  • Table 26: Turbitex C 3c Reagent - Product Description 28
  • Table 27: Turbitex C 4 Reagent - Product Status 28
  • Table 28: Turbitex C 4 Reagent - Product Description 29
  • Table 29: Turbitex CRP Reagent - Product Status 29
  • Table 30: Turbitex CRP Reagent - Product Description 30
  • Table 31: Turbitex CRP Ultra Reagent - Product Status 30
  • Table 32: Turbitex CRP Ultra Reagent - Product Description 31
  • Table 33: Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 34: Access - sFlt-1 Assay - Product Status 33
  • Table 35: Access - sFlt-1 Assay - Product Description 33
  • Table 36: UniCel DxC 600i Synchron Access Clinical System - sFlt-1 Assay - Product Status 33
  • Table 37: UniCel DxC 600i Synchron Access Clinical System - sFlt-1 Assay - Product Description 33
  • Table 38: UniCel DxC 680i Synchron Access Clinical System - PlGF Assay - Product Status 34
  • Table 39: UniCel DxC 680i Synchron Access Clinical System - PlGF Assay - Product Description 34
  • Table 40: UniCel DxC 680i Synchron Access Clinical System - sFlt-1 Assay - Product Status 34
  • Table 41: UniCel DxC 680i Synchron Access Clinical System - sFlt-1 Assay - Product Description 34
  • Table 42: UniCel DxC 860i Synchron Access Clinical System - PlGF Assay - Product Status 35
  • Table 43: UniCel DxC 860i Synchron Access Clinical System - PlGF Assay - Product Description 35
  • Table 44: UniCel DxC 860i Synchron Access Clinical System - sFlt-1 Assay - Product Status 35
  • Table 45: UniCel DxC 860i Synchron Access Clinical System - sFlt-1 Assay - Product Description 36
  • Table 46: UniCel DxC 880i Synchron Access Clinical System - PlGF Assay - Product Status 36
  • Table 47: UniCel DxC 880i Synchron Access Clinical System - PlGF Assay - Product Description 36
  • Table 48: UniCel DxC 880i Synchron Access Clinical System - sFlt-1 Assay - Product Status 37
  • Table 49: UniCel DxC 880i Synchron Access Clinical System - sFlt-1 Assay - Product Description 37
  • Table 50: UniCel DxI 600 Access Immunoassay System - PlGF Assay - Product Status 37
  • Table 51: UniCel DxI 600 Access Immunoassay System - PlGF Assay - Product Description 37
  • Table 52: UniCel DxI 600 Access Immunoassay System - sFlt-1 Assay - Product Status 38
  • Table 53: UniCel DxI 600 Access Immunoassay System - sFlt-1 Assay - Product Description 38
  • Table 54: UniCel DxI 660i Synchron Access Clinical System - sFlt-1 Assay - Product Status 38
  • Table 55: UniCel DxI 660i Synchron Access Clinical System - sFlt-1 Assay - Product Description 38
  • Table 56: UniCel DxI 800 Access Immunoassay System - PlGF Assay - Product Status 39
  • Table 57: UniCel DxI 800 Access Immunoassay System - PlGF Assay - Product Description 39
  • Table 58: UniCel DxI 800 Access Immunoassay System - sFlt-1 Assay - Product Status 39
  • Table 59: UniCel DxI 800 Access Immunoassay System - sFlt-1 Assay - Product Description 40
  • Table 60: UniCel DxI 860i Synchron Access Clinical System - PlGF Assay - Product Status 40

List of Figures

  • Figure 1: Specific Proteins - Pipeline Products by Stage of Development 10
  • Figure 2: Specific Proteins - Pipeline Products by Territory 11
  • Figure 3: Specific Proteins - Pipeline Products by Regulatory Path 12
  • Figure 4: Specific Proteins - Pipeline Products by Estimated Approval Date 13

GlobalData's Medical Devices sector report, "Specific Proteins - Medical Devices Pipeline Assessment, 2019" provides an overview of Specific Proteins currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Specific Proteins pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Specific Proteins under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Specific Proteins and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Specific Proteins under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

  • 1.1 List of Tables 5
  • 1.2 List of Figures 8

2 Introduction 9

  • 2.1 Specific Proteins Overview 9

3 Products under Development 10

  • 3.1 Specific Proteins - Pipeline Products by Stage of Development 10
  • 3.2 Specific Proteins - Pipeline Products by Territory 11
  • 3.3 Specific Proteins - Pipeline Products by Regulatory Path 12
  • 3.4 Specific Proteins - Pipeline Products by Estimated Approval Date 13

4 Specific Proteins - Pipeline Products under Development by Companies 14

  • 4.1 Specific Proteins Companies - Pipeline Products by Stage of Development 14
  • 4.2 Specific Proteins - Pipeline Products by Stage of Development 15

5 Specific Proteins Companies and Product Overview 18

  • 5.1 Abbott Diagnostics Company Overview 18
    • 5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 18
  • 5.2 Alfa Wassermann Diagnostic Technologies, LLC Company Overview 20
    • 5.2.1 Alfa Wassermann Diagnostic Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.3 Amerimmune LLC Company Overview 22
    • 5.3.1 Amerimmune LLC Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.4 Analyticon Biotechnologies AG Company Overview 24
    • 5.4.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.5 Beckman Coulter Inc Company Overview 29
    • 5.5.1 Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.6 China Medical Technologies Inc (Inactive) Company Overview 37
    • 5.6.1 China Medical Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.7 Colorado State University Company Overview 38
    • 5.7.1 Colorado State University Pipeline Products & Ongoing Clinical Trials Overview 38
  • 5.8 Fujirebio Diagnostics Inc Company Overview 39
    • 5.8.1 Fujirebio Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 39
  • 5.9 Genesis Detection Systems, Inc. Company Overview 40
    • 5.9.1 Genesis Detection Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
  • 5.10 Genome Diagnostics Pvt. Ltd. Company Overview 41
    • 5.10.1 Genome Diagnostics Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 41
  • 5.11 Guanine Inc Company Overview 42
    • 5.11.1 Guanine Inc Pipeline Products & Ongoing Clinical Trials Overview 42
  • 5.12 Hologic Inc Company Overview 43
    • 5.12.1 Hologic Inc Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.13 Isoformix Inc Company Overview 44
    • 5.13.1 Isoformix Inc Pipeline Products & Ongoing Clinical Trials Overview 44
  • 5.14 Kobe University Company Overview 45
    • 5.14.1 Kobe University Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.15 Ortho-Clinical Diagnostics Inc Company Overview 46
    • 5.15.1 Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 46
  • 5.16 Ottawa Hospital Research Institute Company Overview 49
    • 5.16.1 Ottawa Hospital Research Institute Pipeline Products & Ongoing Clinical Trials Overview 49
  • 5.17 Roche Diagnostics International Ltd Company Overview 50
    • 5.17.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
  • 5.18 Sebia SA Company Overview 57
    • 5.18.1 Sebia SA Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.19 Siemens Healthcare Diagnostics Inc Company Overview 58
    • 5.19.1 Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 58
  • 5.20 Siemens Healthineers AG Company Overview 66
    • 5.20.1 Siemens Healthineers AG Pipeline Products & Ongoing Clinical Trials Overview 66
  • 5.21 The Binding Site Group Ltd Company Overview 68
    • 5.21.1 The Binding Site Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 68
  • 5.22 Umea University Company Overview 69
    • 5.22.1 Umea University Pipeline Products & Ongoing Clinical Trials Overview 69
  • 5.23 University of California Company Overview 70
    • 5.23.1 University of California Pipeline Products & Ongoing Clinical Trials Overview 70

6 Specific Proteins- Recent Developments 71

  • 6.1 Oct 30, 2019: PerkinElmer announces financial results for the third quarter of 2019 71
  • 6.2 Oct 29, 2019: ELITechGroup announces direct sales and customer support in Canada 72
  • 6.3 Oct 23, 2019: bioMerieux - Third-Quarter 2019 Business Review 72
  • 6.4 Oct 22, 2019: bioMerieux - Third quarter 2019 business review 74
  • 6.5 Oct 21, 2019: SomaLogic significantly expands key strategic collaboration with Novartis 75
  • 6.6 Oct 16, 2019: Abbott reports third-quarter 2019 results 76
  • 6.7 Oct 01, 2019: Opthea receives A$14.6mR&D tax incentive 78
  • 6.8 Sep 04, 2019: bioMerieux announces First-Half 2019 Results 79
  • 6.9 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership 82
  • 6.10 Aug 21, 2019: PerkinElmer announces leadership succession plan 83

7 Appendix 120

  • 7.1 Methodology 120
  • 7.2 About GlobalData 123
  • 7.3 Contact Us 123
  • 7.4 Disclaimer 123
Back to Top
전화 문의
F A Q